Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia

  • STATUS
    Recruiting
  • End date
    Feb 21, 2024
  • participants needed
    600
  • sponsor
    Gruppo Italiano Malattie EMatologiche dell'Adulto
Updated on 21 January 2021

Summary

The study will investigate in newly diagnosed CP-CML patients the efficacy of NIL frontline therapy vs IM followed by switch to NIL in the case of absence of optimal response as defined by the ELN criteria.

Description

This is a prospective, interventional, randomized, two arms, phase IV study evaluating both the depth of the molecular response and the rate of treatment free remission rate in newly diagnosed CP-CML patients treated with NIL or IM followed by switch to NIL in absence of optimal response (defined according the ELN 2013 criteria) as per clinical practice.

The enrolled patients will be randomized 1:1 between NIL and IM. Patients will be stratified according to the Sokal risk score to high versus intermediate/low risk groups. Newly diagnosed patients will be treated according to the registered dose of NIL and IM for frontline chronic phase CML (300 mg BID and 400 mg OAD, respectively). The patients intolerant to IM and the patients without optimal response to IM at 3 months, at 6 months, at 12 months (except the patients with progression to accelerated or blastic phase) will be switched to NIL second line.

The absence of optimal response is defined by at least one of the following ELN criteria: a) Absence of Complete Hematologic Response at 3 months or thereafter; b) Absence of Partial Cytogenetic Response (> 35% Ph+ metaphases) at 3 months; c) BCR-ABL transcript level > 10% according to the IS at 3 months; d) Absence of Complete Cytogenetic Response (> 1% Ph+ metaphases) at 6 months; e) BCR-ABL transcript level > 1% according to the IS at 6 months; f) Absence of Major Molecular Response (MR3.0, transcript level > 0.1% according to the IS) at 12 months.

Treatment choice for the patients with progression to advanced disease phase while on IM and for the patients intolerant to or resistant (including progressions to advanced phases) to NIL will be up to the principal investigator of the participating Center. However, information concerning the course and outcome of these patients will be collected and recorded for at least 5 years, and they could be enrolled in investigational studies promoted by GIMEMA or other sponsors.

After the induction of deep molecular remission phase of therapy, i.e. the first two years of the study, residual disease will be closely monitored (quarterly) by Q-PCR assays. All the patients who obtain a reduction greater than 4.0 logs of residual disease (MR4.0) within the first three years of treatment, and maintain this level of response in all the subsequent tests up to the end of the fourth years of therapy qualify for the discontinuation phase of the study. Therefore, all patients who are in MR4.0 after a four-year period of TKI treatment, that must include in its final part at least one years of maintained MR4.0, defined as 12-month period during which the MR4.0 never is lost in 4 consecutive MRD analyses at three-monthly intervals, will enter the treatment free remission (TFR) phase of the study. In case of loss of MR3.0, the last assumed TKI will be resumed at the same dose.

All patients, including those who do not match the criteria for discontinuation of TKI treatment, will continue the assigned treatment and will be followed for 5 years, starting from the date of enrolment.

Details
Condition Chronyc Myeloid Leukemia
Treatment Imatinib, Nilotinib
Clinical Study IdentifierNCT02602314
SponsorGruppo Italiano Malattie EMatologiche dell'Adulto
Last Modified on21 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients with a confirmed diagnosis of BCR/ABL+ CML in chronic phase
Documented chronic phase CML must meet all the following criteria
< 15% blasts in peripheral blood < 30% blasts plus promyelocytes in peripheral
blood < 20% basophils in the peripheral blood
x 109/L ( 100,000/mm3) platelets
Age 18
ECOG performance status of 0-2
Evidence of typical BCR-ABL transcripts which are amenable to standardized RQ-PCR
Adequate end organ function as defined by
Total bilirubin < 1.5 x ULN (ULN = upper limit of normal in a local
institution lab)
Does not apply to patients with isolated hyperbilirubinemia (e.g., Gilbert's
disease) grade < 3 SGOT (AST) and SGPT (ALT) 3 x ULN Serum amylase and lipase
x ULN Alkaline phosphatase 2.5 x ULN Serum creatinine < 1.5 x ULN
Having completed the QoL baseline evaluation (i.e., before randomization)
Written informed consent prior to any study procedures

Exclusion Criteria

Expression of any atypical BCR-ABL transcripts, instead of the classical P210-encoding type with the e13a2 or the e14a2 junction at screening
Previous treatment with BCR-ABL inhibitors for a period longer than 1 month
Previous anticancer agents (hydroxyurea, anagrelide, interferon) for CML for a time longer than three months
Poorly controlled diabetes mellitus (defined as HbA1c >8%)
Prior documented history of coronary heart disease, including myocardial infarction, coronary bypass, coronary stent, and symptomatic angina
LVEF <45% or below the institutional lower limit of the normal range
(whichever ishigher) Complete left bundle branch block Right bundle branch
block plus left anterior or posterior hemiblock Use of a ventricular-paced
pacemaker Congenital long QT syndrome or a known family history of long QT
syndrome History of or presence of clinically significant ventricular or
atrial tachyarrhythmias
Atrial fibrillation or flutter
Clinically significant resting bradycardia (< 50 beats per minute)
QTc > 450 msec on the average of three serial screening ECGs (using the QTcF formula). If QTcF > 450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and the patient re-tested History or clinical signs of myocardial infarction within 12 months of study entry History of unstable angina within 12 months of study entry Other clinically significant heart disease (e.g. congestive heart failure)
Uncontrolled hypertension is not a heart disease
History of peripheral arterial occlusive disease
History of acute pancreatitis within 12 months of study entry, or a past medical history of chronic pancreatitis
Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers which cannot be either discontinued or switched to a different medication prior to starting study drug
Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and for which cannot be either safely discontinued or switched to a different medication prior to starting study drug
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note